StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Free Report) in a research note released on Monday morning. The firm issued a buy rating on the biotechnology company's stock.
A number of other equities research analysts have also recently weighed in on ADAP. Scotiabank cut their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research note on Friday, March 21st. HC Wainwright decreased their price objective on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Guggenheim lowered their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. Finally, Wells Fargo & Company cut their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a report on Friday, March 21st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Adaptimmune Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $1.83.
Read Our Latest Analysis on Adaptimmune Therapeutics
Adaptimmune Therapeutics Stock Performance
ADAP stock traded up $0.02 during midday trading on Monday, reaching $0.25. The company had a trading volume of 994,301 shares, compared to its average volume of 1,773,186. The firm has a market capitalization of $64.18 million, a PE ratio of -1.13 and a beta of 2.84. Adaptimmune Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.48. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average price of $0.41 and a 200 day moving average price of $0.59.
Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The firm had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. Analysts anticipate that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. Two Seas Capital LP acquired a new position in shares of Adaptimmune Therapeutics in the 4th quarter valued at about $7,992,000. Two Sigma Investments LP boosted its stake in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after buying an additional 19,146 shares during the period. Two Sigma Advisers LP grew its holdings in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 58,787 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Adaptimmune Therapeutics by 87.7% during the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company's stock worth $176,000 after acquiring an additional 152,780 shares in the last quarter. Finally, Long Focus Capital Management LLC boosted its position in Adaptimmune Therapeutics by 54.1% during the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock valued at $11,040,000 after purchasing an additional 7,194,503 shares during the last quarter. Hedge funds and other institutional investors own 31.37% of the company's stock.
About Adaptimmune Therapeutics
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Articles
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
